isaderm pro psy 5/1 mg/g gel
dechra veterinary products a-s - betamethason a antibiotika - gel - kortikosteroidy, silné, kombinace s antibiotiky - psi
belogent 0,5mg/g+1mg/g krém
belupo, s.r.o., bratislava array - 2065 betamethason-dipropionÁt; 656 gentamicin-sulfÁt - krém - 0,5mg/g+1mg/g - betamethason a antibiotika
belogent 0,5mg/g+1mg/g mast
belupo, s.r.o., bratislava array - 2065 betamethason-dipropionÁt; 656 gentamicin-sulfÁt - mast - 0,5mg/g+1mg/g - betamethason a antibiotika
fucicort 20mg/g+1mg/g krém
leo pharma a/s, ballerup array - 13230 hemihydrÁt kyseliny fusidovÉ; 167 betamethason-valerÁt - krém - 20mg/g+1mg/g - betamethason a antibiotika
fucicort lipid 20mg/g+1mg/g krém
leo pharma a/s, ballerup array - 13230 hemihydrÁt kyseliny fusidovÉ; 167 betamethason-valerÁt - krém - 20mg/g+1mg/g - betamethason a antibiotika
purevax rcch
merial - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain) - imunopreparát pro felidae, - kočky - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs and excretion;against chlamydophila felis infection to reduce clinical signs. následky imunitní odpovědi byly prokázány 1 týden po primárním očkování proti rhinotracheitidě, kaliciviru a chlamydophila felis. doba trvání imunity je 1 rok po poslední (opětovné) očkování.
biobos rcc injekční suspenze
bioveta, a.s. - bovine rotavirus + bovine coronavirus + escherichia - injekční suspenze - inaktivované virové a inaktivované bakteriální vakcíny - skot
sutent
pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastická činidla - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.
odomzo
sun pharmaceutical industries europe b.v. - sonidegib difosfát - karcinom, bazální buňka - antineoplastická činidla - přípravek odomzo je určen k léčbě dospělých pacientů s lokálně pokročilým bazocelulárním karcinomem (bcc), kteří nejsou léčeni léčebným nebo radiační terapií.
sunitinib accord
accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastická činidla - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.